LF 08-0299 (tresperimus)

Subscribe to Selected New Research on LF 08-0299

7 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: induces tolerance after short-term treatment in a fully major histocompatibility mismatched rat cardiac allograft model

Also Known As:

tresperimus; (4-((3-aminopropyl)amino)butyl)-2-((6-((aminoiminomethyl)amino)hexyl)amino)-2-oxoethyl carbamic acid ester, trihydrochloride; LF-08-0299

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Related Diseases

1.	Graft vs Host Disease (Graft-Versus-Host Disease) 07/01/2001 - "Tresperimus shows promise in the move from immunosuppression to tolerance induction as the way to prevent transplant rejection and graft versus host disease (G v HD)" 01/01/2001 - "These results may be of clinical interest as tresperimus is currently used in phase I-III studies for the prevention of graft versus host disease in recipients of allogeneic bone marrow." 01/01/2002 - "Bearing in mind that the test drug supports the clonogenic potential of CD34+ cells, the overall findings emphasize the importance of assessing the effect of tresperimus on in vivo long-term hematopoiesis which could predict the potential clinical use of tresperimus in the prevention of graft-versus-host disease in recipients of allogeneic bone marrow." 09/27/1996 - "We investigated the ability of LF 08--0299, a new immunosuppressive compound, to prevent murine graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT)" 09/27/1996 - "Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 09/27/1996 - "We further showed that while LF 08--0299 can protect recipient mice from lethal GVHD, it also preserved a graft-versus-leukemia effect when mice were inoculated with P815 tumor cells" Get all the results and reference details, order at left...
3.	Leukemia 09/27/1996 - "We further showed that while LF 08--0299 can protect recipient mice from lethal GVHD, it also preserved a graft-versus-leukemia effect when mice were inoculated with P815 tumor cells" Get all the results and reference details, order at left...
3 Diseases and 7 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Antigens
2.	LF 08-0299 (tresperimus)
3.	gusperimus
3 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
2.	Transplants (Transplant)
2 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>